Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

NCT01377246
completedphase_2

High Dose Somatostatin Analogues in Neuroendocrine Tumors

NCT00990535
completed

Prediction of Tumor Shrinkage in Acromegaly

NCT00616408
completedphase_4

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

NCT00461149

Clinical Trials (4)

Showing 4 of 4 trials
NCT01377246Phase 3

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency

Completed
NCT00990535Phase 2

High Dose Somatostatin Analogues in Neuroendocrine Tumors

Completed
NCT00616408

Prediction of Tumor Shrinkage in Acromegaly

Completed
NCT00461149Phase 4

Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4